The stock tumbled 13 per cent to Rs 720 on BSE.
Novartis India yesterday reported a standalone net profit of Rs 21.5 crore for the March quarter.
It had posted a net profit of Rs 51.9 crore in the same period a year ago.
"The figures for the year ended March 31, 2016 are not comparable to those of the previous year ended March 31, 2015 on account of sale of OTC and animal health divisions," Novartis India said in a BSE filing.
The board also approved a buyback proposal for up to 38.2 lakh shares of Rs 5 each from all existing shareholders at Rs 760 per share, aggregating at Rs 290.3 crore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%